Arvinas, Inc. (NASDAQ:ARVN) Receives $14.17 Average Price Target from Analysts

Arvinas, Inc. (NASDAQ:ARVN) has been assigned an average rating of “Hold” from the eleven brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.1667.

Several equities research analysts have commented on the company. Weiss Ratings upgraded Arvinas from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, August 13th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $11.00 target price (down from $15.00) on shares of Arvinas in a research note on Tuesday, August 4th. Barclays increased their price target on shares of Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Wedbush lifted their price objective on shares of Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Evercore set a $14.00 price objective on shares of Arvinas in a research report on Monday, August 10th.

Arvinas Stock Performance

NASDAQ ARVN opened at $9.60 on Wednesday. The firm has a market capitalization of $619.39 million, a P/E ratio of 96.01 and a beta of 1.71. The stock has a 50-day simple moving average of $8.45 and a two-hundred day simple moving average of $9.89. Arvinas has a fifty-two week low of $6.97 and a fifty-two week high of $14.51.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, August 4th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95. The firm had revenue of $249.70 million for the quarter, compared to the consensus estimate of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The company’s revenue was up 1014.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.84) earnings per share. As a group, analysts forecast that Arvinas will post 0.05 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Andrew Saik sold 5,696 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $8.16, for a total value of $46,479.36. Following the completion of the transaction, the chief financial officer owned 187,432 shares of the company’s stock, valued at approximately $1,529,445.12. This represents a 2.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ARVN. Hussman Strategic Advisors Inc. purchased a new stake in shares of Arvinas during the fourth quarter worth $1,245,000. Brummer Multi Strategy AB purchased a new position in shares of Arvinas in the fourth quarter worth about $1,973,000. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in Arvinas by 371.0% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 70,650 shares of the company’s stock worth $838,000 after acquiring an additional 55,650 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Arvinas during the second quarter worth about $1,182,000. Finally, Armistice Capital LLC grew its stake in Arvinas by 50.0% during the 4th quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after acquiring an additional 600,000 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.